{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:34Z","timestamp":1790689954823,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221525"],"award-info":[{"award-number":["BK20221525"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004179","name":"Ningxia Medical University","doi-asserted-by":"publisher","award":["XJKF240305"],"award-info":[{"award-number":["XJKF240305"]}],"id":[{"id":"10.13039\/501100004179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574473"],"award-info":[{"award-number":["82574473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070883"],"award-info":[{"award-number":["82070883"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273982"],"award-info":[{"award-number":["82273982"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.metabol.2025.156462","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:38:20Z","timestamp":1764607100000},"page":"156462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["FAM83A acts as an amplifier for lipogenic signaling to facilitate the pathogenesis of metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"175","author":[{"given":"Yang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2025.156462_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156462_bb0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2025.156462_bb0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2025.156462_bb0020","first-page":"S10","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2025.156462_bb0025","first-page":"724","article-title":"Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies","volume":"22","author":"Chen","year":"2024","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.metabol.2025.156462_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101193","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"Desjardins","year":"2023","journal-title":"Cell reports Medicine"},{"key":"10.1016\/j.metabol.2025.156462_bb0035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41401-019-0310-0","article-title":"WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice","volume":"41","author":"Gao","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.metabol.2025.156462_bb0040","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-022-19459-z","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O\u2019Farrell","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156462_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2025.156462_bb0050","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist Saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156462_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2025.156462_bb0060","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41467-023-37142-3","article-title":"Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K\/AKT\/PDGF axis activation in male mice","volume":"14","author":"Ye","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2025.156462_bb0065","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/hep.32179","article-title":"OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways","volume":"75","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156462_bb0070","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3350\/cmh.2022.0068","article-title":"Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- \u03baB signaling pathways","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.metabol.2025.156462_bb0075","doi-asserted-by":"crossref","first-page":"37010","DOI":"10.1289\/EHP8222","article-title":"Effect of epidermal growth factor treatment and polychlorinated biphenyl exposure in a dietary-exposure mouse model of steatohepatitis","volume":"129","author":"Hardesty","year":"2021","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.metabol.2025.156462_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110686","article-title":"Visfatin-induced upregulation of lipogenesis via EGFR\/AKT\/GSK3\u03b2 pathway promotes breast cancer cell growth","volume":"107","author":"Rajput","year":"2023","journal-title":"Cell Signal"},{"key":"10.1016\/j.metabol.2025.156462_bb0085","first-page":"9","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.metabol.2025.156462_bb0090","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1172\/JCI60498","article-title":"FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice","volume":"122","author":"Lee","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2025.156462_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116372","article-title":"Sense and anti-sense: role of FAM83A and FAM83A-AS1 in Wnt, EGFR, PI3K, EMT pathways and tumor progression","volume":"173","author":"Zhao","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2025.156462_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102339","article-title":"Proto-oncogene FAM83A contributes to casein kinase 1-mediated mitochondrial maintenance and white adipocyte differentiation","volume":"298","author":"Huang","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2025.156462_bb0105","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s44318-025-00362-y","article-title":"SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis","volume":"44","author":"Shi","year":"2025","journal-title":"EMBO J"},{"key":"10.1016\/j.metabol.2025.156462_bb0110","doi-asserted-by":"crossref","first-page":"1502263","DOI":"10.3389\/fimmu.2024.1502263","article-title":"Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2025.156462_bb0115","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41388-023-02795-3","article-title":"RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression","volume":"42","author":"Du","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.metabol.2025.156462_bb0120","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00125-022-05735-0","article-title":"Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease","volume":"65","author":"Sandholm","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2025.156462_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41392-023-01405-8","article-title":"FBXW7\u03b2 loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth","volume":"8","author":"Wei","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.metabol.2025.156462_bb0130","first-page":"11","article-title":"FAM83A and FAM83B as prognostic biomarkers and potential new therapeutic targets in NSCLC","author":"Richtmann","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.metabol.2025.156462_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228833","article-title":"Involvement of MicroRNA-1-FAM83A Axis dysfunction in the growth and motility of lung Cancer cells","volume":"21","author":"Liu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2025.156462_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.117189","article-title":"Guben Xiezhuo decoction inhibits M1 polarization through the Raf1\/p-Elk1 signaling axis to attenuate renal interstitial fibrosis","volume":"319","author":"Liu","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.metabol.2025.156462_bb0145","first-page":"29","article-title":"Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation","volume":"19","author":"Boudreau","year":"2007","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.metabol.2025.156462_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156462_bb0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156462_bb0160","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2025.156462_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.919559","article-title":"Pan-cancer analysis of the FAM83 family and its association with prognosis and tumor microenvironment","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.metabol.2025.156462_bb0170","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.18632\/aging.102163","article-title":"FAM83A signaling induces epithelial-mesenchymal transition by the PI3K\/AKT\/snail pathway in NSCLC","volume":"11","author":"Zhou","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.metabol.2025.156462_bb0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/13813455.2014.973418","article-title":"Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2","volume":"120","author":"Knebel","year":"2014","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.metabol.2025.156462_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147849","article-title":"RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics","volume":"131","author":"Bekele","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2025.156462_bb0185","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1038\/s41598-019-49475-5","article-title":"A FAM83A positive feed-back loop drives survival and Tumorigenicity of pancreatic ductal adenocarcinomas","volume":"9","author":"Parameswaran","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2025.156462_bb0190","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.7150\/jca.83420","article-title":"Involvement of FAM83 family proteins in the development of solid tumors: An update review","volume":"14","author":"Jiang","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.metabol.2025.156462_bb0195","first-page":"7508","article-title":"Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF\/ERK and PI3K\/AKT\/mTOR pathways","volume":"13","author":"Huang","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.metabol.2025.156462_bb0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.freeradbiomed.2025.01.047","article-title":"Fasting enhances the efficacy of Sorafenib in breast cancer via mitophagy mediated ROS-driven p53 pathway","volume":"229","author":"Li","year":"2025","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2025.156462_bb0205","doi-asserted-by":"crossref","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","volume":"8","author":"Sung","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.metabol.2025.156462_bb0210","article-title":"Probiotics Mixture, Prohep: a Potential Adjuvant for Low-Dose Sorafenib in Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma Suppression Through Modulating Gut Microbiota","author":"Zhang","year":"2025","journal-title":"Probiotics Antimicrob Proteins"},{"key":"10.1016\/j.metabol.2025.156462_bb0215","article-title":"Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.metabol.2025.156462_bb0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12876-025-03632-5","article-title":"Neuregulin1 ameliorates metabolic dysfunction-associated fatty liver disease via the ERK\/SIRT1 signaling pathways","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.metabol.2025.156462_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916647373","article-title":"Pre-LTP requires extracellular signal-regulated kinase in the ACC","volume":"12","author":"Yamanaka","year":"2016","journal-title":"Mol Pain"},{"key":"10.1016\/j.metabol.2025.156462_bb0230","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1073\/pnas.92.17.7686","article-title":"A synthetic inhibitor of the mitogen-activated protein kinase cascade","volume":"92","author":"Dudley","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.metabol.2025.156462_bb0235","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1172\/JCI60517","article-title":"FAM83B mediates EGFR- and RAS-driven oncogenic transformation","volume":"122","author":"Cipriano","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2025.156462_bb0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.metabol.2025.156462_bb0245","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/hep.32719","article-title":"Intrahepatic paracrine signaling by cardiotrophin-like cytokine factor 1 ameliorates diet-induced NASH in mice","volume":"78","author":"Liu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2025.156462_bb0250","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.metabol.2025.156462_bb0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2025.156462_bb0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jare.2022.08.006","article-title":"ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2\/ERK signaling pathways","volume":"47","author":"Zhang","year":"2023","journal-title":"J Adv Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:21:17Z","timestamp":1781065277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525003312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":52,"alternative-id":["S0026049525003312"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156462","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FAM83A acts as an amplifier for lipogenic signaling to facilitate the pathogenesis of metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156462"}}